Loading…
Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen
The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM). However, stem cell yields after CTD remain inconsistent. The aim of the present study is to identify the influence of the CTD regimen...
Saved in:
Published in: | International journal of hematology 2013, Vol.97 (1), p.92-97 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83 |
---|---|
cites | cdi_FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83 |
container_end_page | 97 |
container_issue | 1 |
container_start_page | 92 |
container_title | International journal of hematology |
container_volume | 97 |
creator | Jung, Sung-Hoon Park, Hyungchul Ahn, Jae-Sook Yang, Deok-Hwan Kim, Mi-Young Kim, Yeo-Kyeoung Kim, Hyeoung-Joon Lee, Je-Jung |
description | The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM). However, stem cell yields after CTD remain inconsistent. The aim of the present study is to identify the influence of the CTD regimen on the outcome of peripheral blood stem cell (PBSC) collection. Fifty-four patients received four cycles of CTD, and PBSCs were mobilized with cyclophosphamide and G-CSF or with G-CSF alone. Each patient from whom ≤4.0 × 10
6
CD34
+
cells/kg were collected received a second mobilization course. The median duration from the start of a CTD regimen to the first collection was 4.3 months. Forty-eight patients were mobilized with cyclophosphamide followed by G-CSF, and six patients were mobilized with G-CSF alone. The median day of apheresis was day 3 (range day 2–day 5). The overall response rate at mobilization was 96.3 %, including 11.1 % complete response, 22.2 % very good partial response, and 63.0 % partial response. The median number of harvested CD34
+
cells was 12.8 × 10
6
cells/kg. At the second mobilization, 88.9 % of patients reached the minimal stem cell collection target of ≥2.0 × 10
6
cells/kg, and 75.9 % of patients achieved the collection target of ≥4.0 × 10
6
cells/kg. CTD within four cycles is an effective primary therapy in patients with newly diagnosed MM and only minimally affects subsequent PBSC collection. |
doi_str_mv | 10.1007/s12185-012-1237-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1271859234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2871221041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EokPhAdggSwgJJAK-xHGyREOhlSqxKWvLsU9mXPkS7IxKeBVelowyQDddndt3Ljo_Qi8p-UAJkR8LZbQVFaGsoozLijxCG9o2ouJS1o_RhnRMVEJScoaelXJLCJWklk_RGeOMcyrEBv2-GAZntJlxGnCZIGAD3uOQeufdLz25FLGLeFw8iFPBd27a4wh3fsbW6V1MBSwOBz-50QMOM_gUNNbDBBlrvL35jN-a2fg07lMZ9zo4C-_xtNfe2bQGOlps4acOsKRLivAOZ9i5APE5ejJoX-DFyZ6j718ubraX1fW3r1fbT9eVqYWYKjFwZoHwzjattN1AueG1kIZxKtteGN13LaV1w62UHCg0sms5Yb2thTUaWn6OXq9zx5x-HKBM6jYdclxWKsrk8uGO8Xqh6EqZnErJMKgxu6DzrChRRznUKoda5FBHORRZel6dJh_6APZfx9__L8CbE6CL0X7IOhpX_nNNR-qmPnJs5cpSijvI9058cPsfyvSj0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1271859234</pqid></control><display><type>article</type><title>Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen</title><source>Springer Nature</source><creator>Jung, Sung-Hoon ; Park, Hyungchul ; Ahn, Jae-Sook ; Yang, Deok-Hwan ; Kim, Mi-Young ; Kim, Yeo-Kyeoung ; Kim, Hyeoung-Joon ; Lee, Je-Jung</creator><creatorcontrib>Jung, Sung-Hoon ; Park, Hyungchul ; Ahn, Jae-Sook ; Yang, Deok-Hwan ; Kim, Mi-Young ; Kim, Yeo-Kyeoung ; Kim, Hyeoung-Joon ; Lee, Je-Jung</creatorcontrib><description>The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM). However, stem cell yields after CTD remain inconsistent. The aim of the present study is to identify the influence of the CTD regimen on the outcome of peripheral blood stem cell (PBSC) collection. Fifty-four patients received four cycles of CTD, and PBSCs were mobilized with cyclophosphamide and G-CSF or with G-CSF alone. Each patient from whom ≤4.0 × 10
6
CD34
+
cells/kg were collected received a second mobilization course. The median duration from the start of a CTD regimen to the first collection was 4.3 months. Forty-eight patients were mobilized with cyclophosphamide followed by G-CSF, and six patients were mobilized with G-CSF alone. The median day of apheresis was day 3 (range day 2–day 5). The overall response rate at mobilization was 96.3 %, including 11.1 % complete response, 22.2 % very good partial response, and 63.0 % partial response. The median number of harvested CD34
+
cells was 12.8 × 10
6
cells/kg. At the second mobilization, 88.9 % of patients reached the minimal stem cell collection target of ≥2.0 × 10
6
cells/kg, and 75.9 % of patients achieved the collection target of ≥4.0 × 10
6
cells/kg. CTD within four cycles is an effective primary therapy in patients with newly diagnosed MM and only minimally affects subsequent PBSC collection.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-012-1237-0</identifier><identifier>PMID: 23233155</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cyclophosphamide - administration & dosage ; Dexamethasone - administration & dosage ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Hematopoietic Stem Cell Mobilization ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple Myeloma - pathology ; Multiple Myeloma - therapy ; Neoplasm Staging ; Oncology ; Original Article ; Remission Induction ; Thalidomide - administration & dosage ; Tissue and Organ Harvesting</subject><ispartof>International journal of hematology, 2013, Vol.97 (1), p.92-97</ispartof><rights>The Japanese Society of Hematology 2012</rights><rights>2014 INIST-CNRS</rights><rights>The Japanese Society of Hematology 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83</citedby><cites>FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26904645$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23233155$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jung, Sung-Hoon</creatorcontrib><creatorcontrib>Park, Hyungchul</creatorcontrib><creatorcontrib>Ahn, Jae-Sook</creatorcontrib><creatorcontrib>Yang, Deok-Hwan</creatorcontrib><creatorcontrib>Kim, Mi-Young</creatorcontrib><creatorcontrib>Kim, Yeo-Kyeoung</creatorcontrib><creatorcontrib>Kim, Hyeoung-Joon</creatorcontrib><creatorcontrib>Lee, Je-Jung</creatorcontrib><title>Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM). However, stem cell yields after CTD remain inconsistent. The aim of the present study is to identify the influence of the CTD regimen on the outcome of peripheral blood stem cell (PBSC) collection. Fifty-four patients received four cycles of CTD, and PBSCs were mobilized with cyclophosphamide and G-CSF or with G-CSF alone. Each patient from whom ≤4.0 × 10
6
CD34
+
cells/kg were collected received a second mobilization course. The median duration from the start of a CTD regimen to the first collection was 4.3 months. Forty-eight patients were mobilized with cyclophosphamide followed by G-CSF, and six patients were mobilized with G-CSF alone. The median day of apheresis was day 3 (range day 2–day 5). The overall response rate at mobilization was 96.3 %, including 11.1 % complete response, 22.2 % very good partial response, and 63.0 % partial response. The median number of harvested CD34
+
cells was 12.8 × 10
6
cells/kg. At the second mobilization, 88.9 % of patients reached the minimal stem cell collection target of ≥2.0 × 10
6
cells/kg, and 75.9 % of patients achieved the collection target of ≥4.0 × 10
6
cells/kg. CTD within four cycles is an effective primary therapy in patients with newly diagnosed MM and only minimally affects subsequent PBSC collection.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Dexamethasone - administration & dosage</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Mobilization</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - pathology</subject><subject>Multiple Myeloma - therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Remission Induction</subject><subject>Thalidomide - administration & dosage</subject><subject>Tissue and Organ Harvesting</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp1kctu1DAUhi0EokPhAdggSwgJJAK-xHGyREOhlSqxKWvLsU9mXPkS7IxKeBVelowyQDddndt3Ljo_Qi8p-UAJkR8LZbQVFaGsoozLijxCG9o2ouJS1o_RhnRMVEJScoaelXJLCJWklk_RGeOMcyrEBv2-GAZntJlxGnCZIGAD3uOQeufdLz25FLGLeFw8iFPBd27a4wh3fsbW6V1MBSwOBz-50QMOM_gUNNbDBBlrvL35jN-a2fg07lMZ9zo4C-_xtNfe2bQGOlps4acOsKRLivAOZ9i5APE5ejJoX-DFyZ6j718ubraX1fW3r1fbT9eVqYWYKjFwZoHwzjattN1AueG1kIZxKtteGN13LaV1w62UHCg0sms5Yb2thTUaWn6OXq9zx5x-HKBM6jYdclxWKsrk8uGO8Xqh6EqZnErJMKgxu6DzrChRRznUKoda5FBHORRZel6dJh_6APZfx9__L8CbE6CL0X7IOhpX_nNNR-qmPnJs5cpSijvI9058cPsfyvSj0A</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Jung, Sung-Hoon</creator><creator>Park, Hyungchul</creator><creator>Ahn, Jae-Sook</creator><creator>Yang, Deok-Hwan</creator><creator>Kim, Mi-Young</creator><creator>Kim, Yeo-Kyeoung</creator><creator>Kim, Hyeoung-Joon</creator><creator>Lee, Je-Jung</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>2013</creationdate><title>Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen</title><author>Jung, Sung-Hoon ; Park, Hyungchul ; Ahn, Jae-Sook ; Yang, Deok-Hwan ; Kim, Mi-Young ; Kim, Yeo-Kyeoung ; Kim, Hyeoung-Joon ; Lee, Je-Jung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Dexamethasone - administration & dosage</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Mobilization</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - pathology</topic><topic>Multiple Myeloma - therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Remission Induction</topic><topic>Thalidomide - administration & dosage</topic><topic>Tissue and Organ Harvesting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jung, Sung-Hoon</creatorcontrib><creatorcontrib>Park, Hyungchul</creatorcontrib><creatorcontrib>Ahn, Jae-Sook</creatorcontrib><creatorcontrib>Yang, Deok-Hwan</creatorcontrib><creatorcontrib>Kim, Mi-Young</creatorcontrib><creatorcontrib>Kim, Yeo-Kyeoung</creatorcontrib><creatorcontrib>Kim, Hyeoung-Joon</creatorcontrib><creatorcontrib>Lee, Je-Jung</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jung, Sung-Hoon</au><au>Park, Hyungchul</au><au>Ahn, Jae-Sook</au><au>Yang, Deok-Hwan</au><au>Kim, Mi-Young</au><au>Kim, Yeo-Kyeoung</au><au>Kim, Hyeoung-Joon</au><au>Lee, Je-Jung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2013</date><risdate>2013</risdate><volume>97</volume><issue>1</issue><spage>92</spage><epage>97</epage><pages>92-97</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM). However, stem cell yields after CTD remain inconsistent. The aim of the present study is to identify the influence of the CTD regimen on the outcome of peripheral blood stem cell (PBSC) collection. Fifty-four patients received four cycles of CTD, and PBSCs were mobilized with cyclophosphamide and G-CSF or with G-CSF alone. Each patient from whom ≤4.0 × 10
6
CD34
+
cells/kg were collected received a second mobilization course. The median duration from the start of a CTD regimen to the first collection was 4.3 months. Forty-eight patients were mobilized with cyclophosphamide followed by G-CSF, and six patients were mobilized with G-CSF alone. The median day of apheresis was day 3 (range day 2–day 5). The overall response rate at mobilization was 96.3 %, including 11.1 % complete response, 22.2 % very good partial response, and 63.0 % partial response. The median number of harvested CD34
+
cells was 12.8 × 10
6
cells/kg. At the second mobilization, 88.9 % of patients reached the minimal stem cell collection target of ≥2.0 × 10
6
cells/kg, and 75.9 % of patients achieved the collection target of ≥4.0 × 10
6
cells/kg. CTD within four cycles is an effective primary therapy in patients with newly diagnosed MM and only minimally affects subsequent PBSC collection.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>23233155</pmid><doi>10.1007/s12185-012-1237-0</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0925-5710 |
ispartof | International journal of hematology, 2013, Vol.97 (1), p.92-97 |
issn | 0925-5710 1865-3774 |
language | eng |
recordid | cdi_proquest_journals_1271859234 |
source | Springer Nature |
subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cyclophosphamide - administration & dosage Dexamethasone - administration & dosage Female Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Middle Aged Multiple Myeloma - pathology Multiple Myeloma - therapy Neoplasm Staging Oncology Original Article Remission Induction Thalidomide - administration & dosage Tissue and Organ Harvesting |
title | Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A06%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20stem%20cell%20mobilization%20in%20patients%20with%20newly%20diagnosed%20multiple%20myeloma%20after%20a%20CTD%20(cyclophosphamide,%20thalidomide,%20and%20dexamethasone)%20regimen&rft.jtitle=International%20journal%20of%20hematology&rft.au=Jung,%20Sung-Hoon&rft.date=2013&rft.volume=97&rft.issue=1&rft.spage=92&rft.epage=97&rft.pages=92-97&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-012-1237-0&rft_dat=%3Cproquest_cross%3E2871221041%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c455t-5f32de039d687d9f13c3457c23178b5cab9811463d773e1e6798302bd45dcae83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1271859234&rft_id=info:pmid/23233155&rfr_iscdi=true |